北京市嘉源律师事务所 关于北京天坛生物制品股份有限公司 2026 年第一次临时股东会的 法律意见书 = 目 西城区复兴门内大街 158 号远洋大厦 4 楼 中国 · 北京 本所及经办律师依据《中华人民共和国证券法》《律师事务所从事证券法律 业务管理办法》和《律师事务所证券法律业务执业规则(试行)》等规定及本法 律意见书出具目以前已经发生或者存在的事实,严格履行了法定职责,遵循了勤 北京 BELIING. 上海 SHANGHAL 深圳 SF ENZHEN·香港 HONGKONG·广州 GUANGZHOU·西安 XI'AN·武汉 WUHAN·长沙 CHANGSH 致:北京天坛生物制品股份有限公司 北京市嘉源律师事务所 关于北京天坛生物制品股份有限公司 2026年第一次临时股东会的法律意见书 嘉源(2026) -04-026 敬启者: 北京市嘉源律师事务所(以下简称"本所")接受北京天坛生物制品股份有 限公司(以下简称"公司")的委托,根据《中华人民共和国公司法》(以下简称 "《公司法》")、《上市公司股东会规则》等现行有效的法律、行政法规、部门规 章、规范性文件(以下简称"法律法规")以及《北京天坛生物制品股份有 ...

格隆汇1月16日｜天坛生物公告，由于工作调整原因，公司原董事长杨汇川先生向董事会提出辞去董事 长、董事会战略与投资委员会主任委员、董事会业绩考核与薪酬委员会委员、董事会提名委员会委员等 职务。辞去上述职务后，杨汇川先生将继续担任公司第九届董事会董事、总经理等职务。上述辞职申请 自送达公司董事会之日起生效。截至本公告披露日，杨汇川先生直接持有本公司46,800股股份，占公司 总股比的0.0024%。 ...

Investment Rating - The report indicates a stable investment outlook for the Japanese Encephalitis (JE) vaccine industry in China, driven by favorable national immunization policies and a concentrated market structure dominated by three major players [1][3]. Core Insights - The continuous optimization of the national immunization program (EPI) is identified as the key driver for the expansion of the JE vaccine market in China, with a significant increase in vaccination coverage and a reduction in disease incidence [3][5]. - The competitive landscape is stabilizing around three leading companies: Liaoning Chengda, Chengdu Biological Products Research Institute, and Kangtai Biological, which collectively hold over 90% market share [3][6]. - New entrants face high barriers to entry due to stringent regulatory requirements and the need for substantial investment in production capacity and distribution networks [4][6]. Summary by Sections National Immunization Policy and Market Dynamics - The JE vaccine market in China has expanded significantly since its inclusion in the EPI, with a reported market growth of approximately 2.8 billion yuan since 2007 due to increased vaccination rates [3]. - The demand for JE vaccines is expected to continue growing as the government aims to include more safe and effective vaccines in the EPI, enhancing the coverage of the population [3][5]. Competitive Landscape - The industry is characterized by a "three strong" market structure, where the leading companies have established significant technological and quality barriers, making it difficult for new entrants to disrupt the market [4][6]. - The focus of competition is shifting from product differentiation to a comprehensive competitive strategy that includes product technology upgrades, supply chain security, and regional penetration capabilities [7]. Vaccine Technology and Production - The JE vaccines in China are primarily categorized into live attenuated vaccines, inactivated vaccines, and mRNA vaccines, with live attenuated vaccines being the mainstay of the national immunization program [16][18]. - The production of JE vaccines relies heavily on standardized cell platforms, which ensure consistency and quality in vaccine manufacturing [30][32]. Vaccination Coverage and Public Health Impact - Vaccination coverage for JE vaccines has remained high, with rates stabilizing around 99% since 2010, indicating strong public health outcomes and effective immunization strategies [14][44]. - The report highlights the need for ongoing efforts to address vaccination gaps in high-risk populations, including rural areas and among migrant populations [44][28].

2026 年第一次临时股东会文件 2026 年第一次临时股东会文件 二零二六年一月 1 2026 年第一次临时股东会文件 2026 年第一次临时股东会会议须知 为维护股东的合法权益，确保北京天坛生物制品股份有限公司（以下 简称"公司"）2026 年第一次临时股东会的正常秩序和议事效率，根据 《中华人民共和国公司法》、中国证券监督管理委员会《上市公司股东会 规则》等法律、法规和《公司章程》的规定，现就会议须知通知如下： 一、董事会以维护全体股东的合法权益、维持会议正常秩序和提高 议事效率为原则，认真履行《公司章程》规定的职责，做好召集、召开 股东会的各项工作。 二、参加股东会的股东（包括股东代表，下同）请按本次股东会会 议通知要求的会议登记方法办理登记手续，出示相应证件，经验证合格 后领取股东会会议资料，方可出席会议。 三、股东请按时进入会场，按工作人员安排入座。 2026 年第一次临时股东会议程 三、会议议题： 四、股东会正式开始后，迟到股东人数、股权额不计入表决数。特 殊情况，应经股东会工作组同意并向见证律师申报同意后方可计入表决 数。 五、股东参加股东会依法享有发言权、咨询权、表决权等各项权利。 股东参加 ...

Market Performance - The biopharmaceutical sector increased by 0.55% on January 6, with Liaoning Chengda leading the gains [1] - The Shanghai Composite Index closed at 4083.67, up by 1.5%, while the Shenzhen Component Index closed at 14022.55, up by 1.4% [1] Individual Stock Performance - Liaoning Chengda (600739) closed at 12.27, with a rise of 7.16% and a trading volume of 530,500 shares, amounting to a transaction value of 633 million yuan [1] - Dongbao Biological (300239) closed at 6.18, up by 5.64%, with a trading volume of 454,500 shares and a transaction value of 278 million yuan [1] - Olin Biological (616889) closed at 27.66, increasing by 3.83%, with a trading volume of 74,400 shares and a transaction value of 204 million yuan [1] - Kanghong Pharmaceutical (002773) closed at 33.75, up by 2.37%, with a trading volume of 249,700 shares and a transaction value of 838 million yuan [1] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 426 million yuan from institutional investors, while retail investors saw a net inflow of 323 million yuan [2] - The net inflow from speculative funds was 104 million yuan [2] Detailed Capital Flow for Selected Stocks - Liaoning Chengda had a net inflow of 34.37 million yuan from institutional investors, while it faced a net outflow of 18.32 million yuan from retail investors [3] - Dongbao Biological saw a net inflow of 21.29 million yuan from institutional investors, with a net outflow of 13.16 million yuan from retail investors [3] - Tian Tan Biological (600161) had a net inflow of 18.06 million yuan from institutional investors, with a net outflow of 10.02 million yuan from retail investors [3]

证券代码：600161 证券简称：天坛生物 公告编号：2025-058 北京天坛生物制品股份有限公司 董事离任公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 北京天坛生物制品股份有限公司（以下简称"公司"）董事会于近日收到公司董事张洁明先生递交的书面 辞职报告。现将有关情况公告如下： 一、提前离任的基本情况 ■ 二、离任对公司的影响 根据《中华人民共和国公司法》和《公司章程》等相关规定，张洁明先生的辞职报告自送达公司董事会 之日起生效，张洁明先生的辞职未导致公司董事会成员低于法定人数，不会影响公司董事会正常运作和 公司正常经营。截至本公告披露日，张洁明先生未持有公司股份，不存在应当履行而未履行的公开承诺 事项。公司及董事会对张洁明先生任职期间为公司发展做出的贡献表示衷心感谢！ 公司已于2025年12月31日召开第九届董事会第二十八次会议，审议通过《关于增补董事的议案》，同意 提名梁红军先生为公司第九届董事会董事，任期至第九届董事会换届。本事项尚需提交将于2026年1月 16日召开的公司2026年第一次临时股东会审议。详见 ...

Group 1 - The company has established a fair and reasonable pricing policy for its related party transactions, adhering to legal regulations and internal management systems [2] - The related party transactions are executed based on principles of fairness, justice, and equity, ensuring no harm to the company or its shareholders [3] - Previous related party transactions have been executed smoothly without any defaults, indicating the capability of the involved parties to fulfill their obligations [1] Group 2 - The company will hold its first extraordinary general meeting of shareholders in 2026 on January 16, with both on-site and online voting options available [6][7] - The meeting will take place at a specified location in Beijing, and shareholders must register in advance to attend [14] - Specific voting procedures are outlined for shareholders, including the use of the Shanghai Stock Exchange's online voting system [8][9]

Group 1 - Lixun Precision plans to repurchase shares worth between 1 billion to 2 billion yuan, with a maximum repurchase price of 86.96 yuan per share, potentially acquiring 11.49 million to 22.99 million shares, representing 0.16% to 0.32% of the total share capital [1] - Zhongwei Company intends to acquire 64.69% of Hangzhou Zhonggui Electronic Technology Co., Ltd. through a combination of issuing shares and cash, with the stock resuming trading on January 5, 2026 [2] - Aowei New Materials announced that its embodied intelligent robot business is not expected to positively impact its 2025 performance, as it is still in the product development stage and has not yet generated revenue [1] Group 2 - Yihui Lithium Energy has postponed the completion date for its 21GWh cylindrical passenger vehicle power battery project to December 31, 2027, due to delays in funding and changes in the economic environment [7] - Shunyu Technology has placed orders for 8,841 GPU products, with a target of 10,000 units per year for 2024 and 2025 [5][6] - Haichuang Bio plans to acquire 51% stakes in seven dental chain companies for 61.2 million yuan, which is expected to positively impact its 2026 performance by adding approximately 100 million yuan in revenue and over 7 million yuan in net profit [19] Group 3 - Guangzhu Port expects to achieve a 11.6% year-on-year increase in container throughput and a 6.2% increase in cargo throughput for 2025 [32] - Tianzhu Materials anticipates a net profit increase of 127.31% to 230.63% for 2025, driven by the growing demand in the new energy vehicle and energy storage markets [30] - The company Zhaoyi Innovation plans to issue 28,915,800 H-shares in Hong Kong, with trading expected to start on January 13, 2026 [33]

同时，天坛生物召开董事会会议，同意提名梁红军为公司第九届董事会董事，任期至第九届董事会换 届。 北京商报讯（记者 王寅浩 宋雨盈）12月31日，天坛生物发布公告称，张洁明因工作调整原因辞去公司 董事职务，原定任期到期日为2026年5月24日。离任后，张洁明不再在公司及其控股子公司任职。 ...

证券代码：600161 证券简称：天坛生物 公告编号：2025-059 北京天坛生物制品股份有限公司 第九届董事会第二十八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京天坛生物制品股份有限公司（以下简称"公司"）第九届董事会第二十八次 会议于 2025 年 12 月 19 日发出会议通知，于 2025 年 12 月 31 日以现场与视频结合方 式在北京市朝阳区双桥路乙 2 号院办公楼一层第十会议室召开。会议由董事长杨汇川 先生主持，会议应到董事八人，实到董事八人。会议出席人数符合《公司法》及《公 司章程》规定的有效人数，会议按预定程序审议了议程中全部议案。会议做出决议如 下： 一、审议通过《关于增补董事的议案》 本议案已经董事会提名委员会事前认可。 同意提名梁红军先生担任公司第九届董事会董事，任期至第九届董事会换届。（简 历附后） 同意将本议案提交股东会审议。 表决结果：8 票同意，0 票反对，0 票弃权。 二、审议通过《关于聘任总经理的议案》 本议案已经董事会提名委员会事前认可。 同意聘任杨汇川先生为公 ...